🧠 TXG Stock Pick: 11-Criteria Deep Dive
Current price: $10.78 | Nov 2025 LEAPS 7.5 call ($4.10, Δ≈0.80)
1. 📉 RSI Oversold (≤30), Now Rebounding
RSI reached oversold levels (~21) recently—started rebounding finance.yahoo.com+9directorstalkinterviews.com+9gurufocus.com+9.
Now sits around 62—well off oversold but confirms bounce initiation .
2. 📈 MACD at Valley & Turning Up
No explicit MACD data found.
RSI surge and price stabilization suggest potential MACD recovery; needs chart confirmation.
3. 🏦 High Institutional Ownership + Recent Buying
Institutional ownership ~84.7% nasdaq.com+15marketbeat.com+15marketbeat.com+15marketwatch.com.
Notable Q1 inflows: Signaturefd, GAMMA, PNC increased stakes marketbeat.com.
4. 🧑💼 TXG Insider Buying in Recent Weeks
Mixed: CFO/CEO sold ~20K shares in May/Feb finance.yahoo.com.
Director Alan Mateo bought 40K shares at
$11.14 in Feb ($446K) marketbeat.com.✅ Partial: some insider buying, but overshadowed by larger insider sells.
5. 📊 Analysts Raising Targets Recently
Consensus target ~$15.81 (~47% upside) fintel.io.
No confirmed recent target upgrades in past weeks—potentially unmet.
6. 🎯 Near-Term Catalysts Emerging
Last major event: Bruker settlement in May.
No new earnings or product launches within the next weeks highlighted.
7. 💡 Recession-Resilient & Emerging Tech
Operates in genomics tech—a durable & growing biotech framework.
Not fully recession-proof but part of emerging/business-critical tech.
8. 💵 Solid Fundamentals & Cash Flow
Q1 ’25 revenue: $155M (beat), but still operating at a $36¢ per-share loss redcircle.com+2marketbeat.com+2sec.gov+2.
2024: $610M revenue vs. $183M loss—cash burn continues finance.yahoo.com.
❌ Weak on profitability/cash generation.
9. 📈 Options Flow: Calls > Puts OI & Volatility
Most active contracts: June/Nov puts at 7.5 strike, limited call volume optioncharts.io+2nasdaq.com+2stockoptionschannel.com+2.
Market Chameleon indicates mixed volume; no clear call dominance marketchameleon.com+1stockoptionschannel.com+1.
10. 🔻 Recent Drop, Stabilizing, Plus Institutional Buy
Fell from $40s to $9–11; now stabilizing above $10 with bounce signs sec.gov+1marketbeat.com+1.
Institutional inflows support stability.
11. 🧨 Liquid LEAPS Calls (Nov ’25) vs. Puts
LEAPS exist (Nov 7.5 & 12.5 strikes); OI moderate sec.gov.
No clear call-heavy liquidity—watch for spread and execution issues.
✅ Scorecard: Criteria Met
| # | Criterion | Met? |
|---|---|---|
| 1 | RSI bounce | ✅ |
| 2 | MACD recovery | ⚠️ |
| 3 | Institutional strong | ✅ |
| 4 | Insider buying | ⚠️ |
| 5 | Analyst upgrades | ⚠️ |
| 6 | Catalysts near-term | ⚠️ |
| 7 | Emerging tech | ✅ |
| 8 | Strong fundamentals | ❌ |
| 9 | Options call flow | ❌ |
| 10 | Bounce after drop | ✅ |
| 11 | LEAPS calls liquidity | ⚠️ |
Total positive: 5 / 11 (+3 partials)
🧭 Final Analysis for TXG
Strengths: Current rebound from oversold levels, deep institutional interest, and a core position in emerging genomics tech make TXG appealing for a technically oriented swing or LEAPS trade.
Weaknesses: Weak profitability, absent insider appetite beyond one director, limited near-term catalysts, and tepid call-dominated options flow.
🧩 Recommendation
Active LEAPS traders: The Nov 2025 $7.50 call at ~$4.10 offers leveraged upside with ~30% buffer—but options liquidity is moderate, so beware bid-ask spreads.
Core equity holders: Consider scaling in modestly; ride the technical bounce while watching the next catalyst (e.g., Q2 earnings in July).
Learn more about LEAPS Strategy in our Stock Options Education Series.
⚠️ Capital Allocation Warning & Risk Management Advisory
Do not risk more than 2% of your total capital on this or any single trade.
Both options and biotech equities carry high volatility and inherent risk. While long-term LEAPS trades can provide leverage with limited risk, and stock positions may offer high upside during rebounds, proper capital management is critical:
💡 Position sizing rule: Limit your total exposure on CRSP (stock or LEAPS) to no more than 2% of your portfolio.
🛑 Use defined-risk setups and avoid emotional averaging down.
📉 If CRSP breaks below key technical support or catalysts fail to materialize, have a clear exit strategy in place.
📜 Disclaimer
This content is for educational and informational purposes only and should not be considered financial advice or a recommendation to buy or sell any securities. Always conduct your own due diligence and consult with a licensed financial advisor before making investment decisions. Past performance is not indicative of future results. You are solely responsible for any investment decisions you make.
